TY - JOUR T1 - Turnover modulates the need for a cost of resistance in adaptive therapy JF - bioRxiv DO - 10.1101/2020.01.22.914366 SP - 2020.01.22.914366 AU - Maximilian Strobl AU - Jeffrey West AU - Yannick Viossat AU - Mehdi Damaghi AU - Mark Robertson-Tessi AU - Joel Brown AU - Robert Gatenby AU - Philip Maini AU - Alexander Anderson Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/03/18/2020.01.22.914366.abstract N2 - “Control and conquer” - this is the philosophy behind adaptive therapy, which seeks to exploit intra-tumoural competition to avoid, or at least, delay the emergence of therapy resistance in cancer. Motivated by promising results from theoretical, experimental and, most recently, a clinical study in prostate cancer, there is an increasing interest in extending this approach to other cancers. As such, it is urgent to understand the characteristics of a cancer which determine whether it will respond well to adaptive therapy, or not. A plausible candidate for such a selection criterion is the fitness cost of resistance. In this paper, we study a simple competition model between sensitive & resistant cell populations to investigate whether the presence of a cost is a necessary condition for adaptive therapy to extend the time to progression beyond that of a standard-of-care continuous therapy. We find that for tumours close to their environmental carrying capacity such a cost of resistance is not required. However, for tumours growing far from carrying capacity, a cost may be required to see meaningful gains. Notably, we show that in such cases it is important to consider the cell turnover in the tumour and we discuss its role in modulating the impact of a cost of resistance. Overall, our work helps to clarify under which circumstances adaptive therapy may be beneficial, and suggests that turnover may play an unexpectedly important role in the decision making process. ER -